199 related articles for article (PubMed ID: 21765641)
21. Bioterrorism. Smallpox vaccinations: how much protection remains?
Cohen J
Science; 2001 Nov; 294(5544):985. PubMed ID: 11691969
[No Abstract] [Full Text] [Related]
22. Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.
Grosenbach DW; Jordan R; King DS; Berhanu A; Warren TK; Kirkwood-Watts DL; Tyavanagimatt S; Tan Y; Wilson RL; Jones KF; Hruby DE
Vaccine; 2008 Feb; 26(7):933-46. PubMed ID: 18226434
[TBL] [Abstract][Full Text] [Related]
23. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.
Seaman MS; Wilck MB; Baden LR; Walsh SR; Grandpre LE; Devoy C; Giri A; Noble LC; Kleinjan JA; Stevenson KE; Kim HT; Dolin R
J Infect Dis; 2010 May; 201(9):1353-60. PubMed ID: 20350190
[TBL] [Abstract][Full Text] [Related]
24. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
[TBL] [Abstract][Full Text] [Related]
25. Generation of an attenuated Tiantan vaccinia virus by deletion of the ribonucleotide reductase large subunit.
Kan S; Jia P; Sun L; Hu N; Li C; Lu H; Tian M; Qi Y; Jin N; Li X
Arch Virol; 2014 Sep; 159(9):2223-31. PubMed ID: 24677065
[TBL] [Abstract][Full Text] [Related]
26. Freeze-dried live attenuated smallpox vaccine prepared in cell culture "LC16-KAKETSUKEN": Post-marketing surveillance study on safety and efficacy compliant with Good Clinical Practice.
Nishiyama Y; Fujii T; Kanatani Y; Shinmura Y; Yokote H; Hashizume S
Vaccine; 2015 Nov; 33(45):6120-7. PubMed ID: 26455406
[TBL] [Abstract][Full Text] [Related]
27. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
[TBL] [Abstract][Full Text] [Related]
28. Smallpox subunit vaccine produced in Planta confers protection in mice.
Golovkin M; Spitsin S; Andrianov V; Smirnov Y; Xiao Y; Pogrebnyak N; Markley K; Brodzik R; Gleba Y; Isaacs SN; Koprowski H
Proc Natl Acad Sci U S A; 2007 Apr; 104(16):6864-9. PubMed ID: 17428917
[TBL] [Abstract][Full Text] [Related]
29. Effect of the Route of Administration of the Vaccinia Virus Strain LIVP to Mice on Its Virulence and Immunogenicity.
Shchelkunov SN; Yakubitskiy SN; Sergeev AA; Kabanov AS; Bauer TV; Bulychev LE; Pyankov SA
Viruses; 2020 Jul; 12(8):. PubMed ID: 32722032
[TBL] [Abstract][Full Text] [Related]
30. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine.
Ferrier-Rembert A; Drillien R; Tournier JN; Garin D; Crance JM
Vaccine; 2008 Mar; 26(14):1794-804. PubMed ID: 18336966
[TBL] [Abstract][Full Text] [Related]
31. An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection.
Morikawa S; Sakiyama T; Hasegawa H; Saijo M; Maeda A; Kurane I; Maeno G; Kimura J; Hirama C; Yoshida T; Asahi-Ozaki Y; Sata T; Kurata T; Kojima A
J Virol; 2005 Sep; 79(18):11873-91. PubMed ID: 16140764
[TBL] [Abstract][Full Text] [Related]
32. Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.
Shinoda K; Wyatt LS; Irvine KR; Moss B
Virol J; 2009 Mar; 6():28. PubMed ID: 19257896
[TBL] [Abstract][Full Text] [Related]
33. A novel, killed-virus nasal vaccinia virus vaccine.
Bielinska AU; Chepurnov AA; Landers JJ; Janczak KW; Chepurnova TS; Luker GD; Baker JR
Clin Vaccine Immunol; 2008 Feb; 15(2):348-58. PubMed ID: 18057181
[TBL] [Abstract][Full Text] [Related]
34. Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.
Meseda CA; Atukorale V; Kuhn J; Schmeisser F; Weir JP
PLoS One; 2016; 11(2):e0149364. PubMed ID: 26895072
[TBL] [Abstract][Full Text] [Related]
35. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination.
Vijaysri S; Jentarra G; Heck MC; Mercer AA; McInnes CJ; Jacobs BL
Vaccine; 2008 Jan; 26(5):664-76. PubMed ID: 18096276
[TBL] [Abstract][Full Text] [Related]
36. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
Kaufman DR; Goudsmit J; Holterman L; Ewald BA; Denholtz M; Devoy C; Giri A; Grandpre LE; Heraud JM; Franchini G; Seaman MS; Havenga MJ; Barouch DH
J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
[TBL] [Abstract][Full Text] [Related]
37. Single-shot immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection.
Rudraraju R; Ramsay AJ
Vaccine; 2010 Jul; 28(31):4997-5004. PubMed ID: 20653083
[TBL] [Abstract][Full Text] [Related]
38. Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax.
Midgley CM; Putz MM; Weber JN; Smith GL
J Gen Virol; 2008 Dec; 89(Pt 12):2992-2997. PubMed ID: 19008384
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
Walsh SR; Wilck MB; Dominguez DJ; Zablowsky E; Bajimaya S; Gagne LS; Verrill KA; Kleinjan JA; Patel A; Zhang Y; Hill H; Acharyya A; Fisher DC; Antin JH; Seaman MS; Dolin R; Baden LR
J Infect Dis; 2013 Jun; 207(12):1888-97. PubMed ID: 23482644
[TBL] [Abstract][Full Text] [Related]
40. Serological Immunity to Smallpox in New South Wales, Australia.
Costantino V; Trent MJ; Sullivan JS; Kunasekaran MP; Gray R; MacIntyre R
Viruses; 2020 May; 12(5):. PubMed ID: 32443405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
